Global Adalimumab Biosimilar Market Report and Forecast 2024-2032

Global Adalimumab Biosimilar Market Outlook

The global adalimumab biosimilar market is expected to grow at a CAGR of about 17.60% in the forecast period of 2024-2032, driven by the rising incidence of rheumatoid arthritis, especially amongst the rapidly growing geriatric population.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

North America, Asia Pacific, and Europe to be the Significant Regional Markets for Adalimumab Biosimilar

North America is expected to be one of the largest markets, owing to numerous large-scale testing laboratories worldwide. The rising incidence of rheumatoid arthritis and the growing geriatric population are among the major factors which are fuelling the market expansion in North America.

Due to extensive commercial advancements and growing biotechnology corporations in the province, Asia Pacific is anticipated to register sturdy growth over the projection period. The increasing focus to develop generic and biosimilar products in the emerging nations of Asia Pacific is estimated to fuel the global adalimumab biosimilar industry in the region.

Europe is expected to grow faster due to the rise in approvals of the new biosimilars, the ageing population, and increasing investments in the research and development of the new adalimumab biosimilars. For instance, in October 2018, Amgen Inc. launched AMGEVITA, a biosimilar of adalimumab.

Adalimumab Biosimilar: Market Segmentation

Adalimumab is a monoclonal antibody used to treat autoimmune illnesses, such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and others. It accomplishes this by blocking Tumour Necrosis Factor (TNF), a soluble inflammatory cytokine. This drug helps prevent further joint injury and preserve joint function by lowering joint swelling.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

By product, the market includes:

• Exemptia
• Adalirel
• Cipleumab
• Others

The several distribution channels of the market are:

• Hospital Pharmacies
• Retail Pharmacies
• Others

The regional markets for the adalimumab biosimilar industry can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The Proliferation of Skin Disorders Augmenting the Market Growth

The most frequent illnesses that harm human health are skin disorders. Many skin disorders lead to lifelong disfigurement, stigma, and disability, and treating them effectively has become a significant concern for health organizations. In this context, a biosimilar of adalimumab has emerged as a feasible therapy option for persistent skin conditions like eczema. This aspect can significantly increase the size of the global adalimumab biosimilar industry throughout the forecast period. The multiple advantages, especially in treating psoriasis, adalimumab biosimilar is a preferred option for tackling skin disorders. The rising geriatric population and increasing public and private investment in pharmaceuticals will propel the market growth. Regulatory approvals for novel products motivate other companies to invest more in research and development and produce new inventions. Some global adalimumab biosimilar industry competitors are already working on new product development and portfolio expansion. For example, through a licencing deal with Cadila Healthcare, Glenmark Pharmaceuticals introduced ADALY, its adalimumab biosimilar medicine, in Mumbai in January 2018.

Key Industry Players in the Global Adalimumab Biosimilar Market

The report gives a detailed analysis of the following key players in the global adalimumab biosimilar industry, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• Alfred E. Tiefenbacher (GmbH & Co. KG)
• Amgen Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• Cadila Pharmaceuticals Ltd.
• Torrent Pharmaceuticals Ltd.
• Reliance Life Sciences Private Limited
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report

Adalimumab Biosimilar Market Report Snapshots

Adalimumab Biosimilar Market Size

Adalimumab Biosimilar Market Companies